Evidence map›Paper›PMID 33332370›Full record

ArticlePloS one2020

Geographical distribution of Enterobacterales with a carbapenemase IMP-6 phenotype and its association with antimicrobial use: An analysis using comprehensive national surveillance data on antimicrobial resistance.

Aki Hirabayashi, Koji Yahara, Toshiki Kajihara, Motoyuki Sugai, Keigo Shibayama

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Phenotypic and Genetic Characteristics ofInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. High-risk clonal expansion of IMP-producingAntimicrobial agents and chemotherapy · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular Epidemiology of Carbapenem-ResistantInternational journal of molecular sciences · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aki HirabayashiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0003-3115-0645
Koji YaharaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Toshiki KajiharaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Motoyuki SugaiAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Keigo ShibayamaAntimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
National Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterobacterales resistant to carbapenems, a class of last-resort antimicrobials, are ranked as an "urgent" and "critical" public health hazard by CDC and WHO. IMP-type carbapenemase-containing Enterobacterales are endemic in Japan, and blaIMP-6 is one of the notable carbapenemase genes responsible for the resistance. The gene is plasmid-encoded and confers resistance to meropenem, but not to imipenem. Therefore, IMP-6-producing Enterobacterales isolates are occasionally overlooked in clinical laboratories and are referred to as 'stealth-type'. Since previous reports in Japan were confined only to some geographical regions, their distribution across prefectures and the factors affecting the distribution remain unclear. Here, we revealed the dynamics of the geographical distribution of Enterobacterales with IMP-6 phenotype associated with antimicrobial use in Japan. We utilized comprehensive national surveillance data of all routine bacteriological test results from more than 1,400 hospitals in 2015 and 2016 to enumerate Escherichia coli and Klebsiella pneumoniae isolates with the antimicrobial susceptibility pattern (phenotype) characteristic of IMP-6 (imipenem susceptible, meropenem resistant), and to tabulate the frequency of isolates with the phenotype for each prefecture. Isolates were detected in approximately half of all prefectures, and combined analysis with the national data of antimicrobial usage revealed a statistically significant association between the frequency and usage of not carbapenems but third-generation cephalosporins (p = 0.006, logistic mixed-effect regression) and a weaker association between the frequency and usage of fluoroquinolones (p = 0.043). The usage of third-generation cephalosporins and fluoroquinolones may select the strains with the IMP-6 phenotype, and contribute to their occasional spread. We expect the findings will promote antimicrobial stewardship to reduce the spread of the notable carbapenemase gene.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsEnterobacteriaceaeEnterobacteriaceae InfectionsEscherichia coliEscherichia coli InfectionsHumansImipenemJapanKlebsiella InfectionsKlebsiella pneumoniaeMeropenemPhenotypeAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsImipenemMeropenem

Identifiers

PMID33332370
PMCPMC7745981
OpenAlexW3112877350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.